Home Antibody All anti-CDKN2A antibodies
Also for CDKN2A (NM_000077)
|CDKN2A antibody was raised against an 18 amino acid peptide from near the amino terminus of human CDKN2A.|
|Human, Mouse, Rat
||ELISA, WB: 1 - 2 ug/ml, IF: 20 ug/ml
|PBS containing 0.02% sodium azide.|
|Affinity chromatography purified via peptide column
|Homo sapiens cyclin-dependent kinase inhibitor 2A (CDKN2A), transcript variant 1|
|ARF; CDK4I; CDKN2; CMM2; INK4; INK4A; MLM; MTS-1; MTS1; P14; P14ARF; P16; P16-INK4A; P16INK4;|
Entrez Gene 1029 Human
Entrez Gene 12578 Mouse
Entrez Gene 25163 Rat
|The CDKN2A locus gives rise to 2 distinct transcripts from different promoters. The transcripts have been designated p16(INK4A) and p14(ARF). This chromosomal region undergoes a number of inversions, translocations, heterozygous deletions, and homozygous deletions in a variety of malignant cell lines including those from glioma, non-small cell lung cancer, leukemia, and melanoma. Deletion of the region containing CDKN2A is found in more than half of all melanoma cell lines. Conversely, transfection of CDKN2A suppressed the growth of two independent mesothelioma cell lines, suggesting that inactivation of the CDKN2 gene is an essential step in the etiology of malignant mesotheliomas. CDKN2A induces a G1 cell cycle arrest by inhibiting the phosphorylation of the Rb protein by the cyclin-dependent kinases CDK4 and CDK6. CDKN2A is expressed as at least three distinct isoforms.|
|Druggable Genome Cell cyclep53 signaling pathwayPathways in cancerPancreatic cancerGliomaMelanomaMore Pathways >> |
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis of CDKN2A in C2C12 cell lysate with CDKN2A antibody at (A) 1 and (B) 2 ug/mL.
Immunofluorescence of CDKN2A in human colon tissue with CDKN2A antibody at 20 ug/mL.